Filip Matthijssens
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Filip Matthijssens has a total of 344 co-authors. Here are the top co-authors by number of shared publications:
- Pieter Van Vlierberghe
Department of Biomolecular Medicine Ghent University Ghent Belgium
48 shared publications - Steven Goossens
Ghent University, Ghent, Belgium
45 shared publications - Barbara De Moerloose
Department of Pediatric Hematology-Oncology and Stem Cell Transplantation, Ghent University Hospital, Ghent, Belgium
40 shared publications - Filip Van Nieuwerburgh
Laboratory of Pharmaceutical Biotechnology, Faculty of Pharmaceutical Sciences, Ghent University, Ghent, Belgium
38 shared publications - Juliette Roels
Department of Biomolecular Medicine, Ghent University, Ghent, Belgium
38 shared publications - Bart Ghesquière
KU Leuven
36 shared publications
Latest Publications
- Open Access
- 24 July 2026
- Published by Elsevier in SSRN Electronic Journal
Long-Term Safety and Efficacy of Efgartigimod in Adults with Primary Immune Thrombocytopenia: Interim Results of the ADVANCE IV+ Phase 3 Trial
Background: ADVANCE IV+ (NCT04225156) is an ongoing, phase 3, open-label extension of the ADVANCE IV trial to assess long-term safety and efficacy of efgartigimod in adults (≥18 years) with chronic or persistent immune thrombocytopenia (ITP; platelet count <30 × 109/L).Methods: In ADVANCE IV, participants were randomised 2:1 to receive intravenous (IV) efgartigimod (10 mg/kg) or placebo once weekly (QW) for weeks 1–4, then QW or every other week (Q2W), based on platelet counts, up to week 24. Participants completing ADVANCE IV and meeting inclusion criteria could roll over to ADVANCE IV+. All participants received efgartigimod IV (10 mg/kg) QW or Q2W, dependent upon platelet counts. The primary objective was safety (frequency/severity of treatment-emergent adverse events [TEAEs]; vital signs; laboratory assessments); secondary objectives included assessment of long-term efficacy.Findings: In this interim analysis (data cutoff: 1 September 2023), 101 individuals (mean [standard deviation] age: 49∙7 [17∙2] years) rolled over from ADVANCE IV: 63 from the efgartigimod treatment group (EFG–EFG) and 38 from the placebo group (PBO–EFG). Most (96/101 [95∙0%]) were white and 51∙5% (52/101) were male. The majority of participants (93/101 [92∙1%]) reported one or more TEAE, with most mild or moderate in severity. Serious adverse events (AEs) were reported by 16/101 participants (15∙8%) (EFG–EFG: 10/63 [15∙9%]; PBO–EFG: 6/38 [15∙8%]). Severe (grade ≥3) AEs were reported by 19 participants (18∙8%) (EFG–EFG: 11/63 [17∙5%]; PBO–EFG: 8/38 [21∙1]). There were no treatment-related deaths. A sustained platelet count response (≥50 × 109/L for ≥4/6 weeks between weeks 19 and 24) was observed in 33/101 participants (32∙7%) (EFG–EFG: 23/63 [36∙5%]; PBO–EFG: 10/38 [26∙3%]). The proportion of sustained platelet count responders remained stable throughout the trial.Interpretation: ADVANCE IV+ demonstrated long-term safety and efficacy of efgartigimod in individuals with chronic or persistent ITP, highlighting its value as a treatment option in this patient group.
- 24 July 2026
- Published by Elsevier in SSRN Electronic Journal
Open AccessLong-Term Safety and Efficacy of Efgartigimod in Adults with Primary Immune Thrombocytopenia: Interim Results of the ADVANCE IV+ Phase 3 Trial
Background: ADVANCE IV+ (NCT04225156) is an ongoing, phase 3, open-label extension of the ADVANCE IV trial to assess long-term safety and efficacy of efgartigimod in adults (≥18 years) with chronic or persistent immune thrombocytopenia (ITP; platelet count <30 × 109/L).Methods: In ADVANCE IV, participants were randomised 2:1 to receive intravenous (IV) efgartigimod (10 mg/kg) or placebo once weekly (QW) for weeks 1–4, then QW or every other week (Q2W), based on platelet counts, up to week 24. Participants completing ADVANCE IV and meeting inclusion criteria could roll over to ADVANCE IV+. All participants received efgartigimod IV (10 mg/kg) QW or Q2W, dependent upon platelet counts. The primary objective was safety (frequency/severity of treatment-emergent adverse events [TEAEs]; vital signs; laboratory assessments); secondary objectives included assessment of long-term efficacy.Findings: In this interim analysis (data cutoff: 1 September 2023), 101 individuals (mean [standard deviation] age: 49∙7 [17∙2] years) rolled over from ADVANCE IV: 63 from the efgartigimod treatment group (EFG–EFG) and 38 from the placebo group (PBO–EFG). Most (96/101 [95∙0%]) were white and 51∙5% (52/101) were male. The majority of participants (93/101 [92∙1%]) reported one or more TEAE, with most mild or moderate in severity. Serious adverse events (AEs) were reported by 16/101 participants (15∙8%) (EFG–EFG: 10/63 [15∙9%]; PBO–EFG: 6/38 [15∙8%]). Severe (grade ≥3) AEs were reported by 19 participants (18∙8%) (EFG–EFG: 11/63 [17∙5%]; PBO–EFG: 8/38 [21∙1]). There were no treatment-related deaths. A sustained platelet count response (≥50 × 109/L for ≥4/6 weeks between weeks 19 and 24) was observed in 33/101 participants (32∙7%) (EFG–EFG: 23/63 [36∙5%]; PBO–EFG: 10/38 [26∙3%]). The proportion of sustained platelet count responders remained stable throughout the trial.Interpretation: ADVANCE IV+ demonstrated long-term safety and efficacy of efgartigimod in individuals with chronic or persistent ITP, highlighting its value as a treatment option in this patient group.